The invention relates to crystalline forms of 4-((R)-2-[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4 carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester hydrochloride, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms and their use as a medicament, especially as a P2Y12 receptor antagonist.
本发明涉及 4-((R)-2-[6-((S)-3-甲氧基-
吡咯烷-1-基)-2-苯基-
嘧啶-4-羰基]-
氨基}-3-膦酰基丙酰基)-
哌嗪-1-
羧酸丁酯盐酸盐的结晶形式、其制备工艺、包含上述结晶形式的药物组合物、由上述结晶形式制备的药物组合物及其作为药物(尤其是作为 P2Y12 受体拮抗剂)的用途。